To assess the effects of Xuesaitong soft capsules on platelet function, clinical efficacy, prognosis, and safety in the treatment of acute coronary syndrome, 400 patients with acute coronary syndrome who underwent PCI were treated with Xuesaitong soft capsules (mainly containing ginsenosides) for 12 weeks.
Patients diagnosed with acute ST-segment elevation myocardial infarction, acute non-ST-segment elevation myocardial infarction, or unstable angina according to Western medical standards. Inclusion Criteria.
Within 4 weeks post-PCI.
Aged between 18 and 80 years, both male and female.
Voluntarily participating in the clinical trial, having signed the informed consent form.
Uncontrolled hypertension after medication (systolic BP >180mmHg or diastolic BP > 110mmHg).
Increased bleeding risk: history of hemorrhagic stroke; intracranial aneurysm; major trauma or surgery within the past month (including Exclusion Criteria bypass surgery); active bleeding disorders.
History of gastrointestinal ulcers or significant gastrointestinal bleeding.
Severe organic heart disease, such as LVEF < 35% or NYHA/Killip heart function grade IV.